TOXINS 2015: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins
January 14-17, 2015  Lisbon, Portugal

www.neurotoxins.org/toxins-2015/

IAB Attendance:

Board of Directors: Dirk Dressler, MD, PhD

Parallel Track II (Clinical)
14:30 – 16:10	Application of BoNT for the Treatment of Cerebral Palsy Chair: Ann Tilton (New Orleans, LA, USA)
14:30 – 14:55	Evidence-Based Review of Safety and Efficacy in Cerebral Palsy Ann Tilton (New Orleans, LA, USA)
14:55 – 15:20	Optimizing Outcomes With Adjunctive Therapy Anthony Ward (Stoke-on-Trent, UK)
15:20 – 15:45	Special Considerations: Dosing Limits and Reasons that Children Discontinue Therapy Florian Heinen (Munich, Germany)
15:45 – 16:10	Managing Drooling in Cerebral Palsy Steffen Berweck (Vogtareuth, Germany)

Parallel Track – Clinical (Workshop D)
14:30 – 16:00	Techniques for Localizing Muscles for BoNT Injection: Demonstration Workshop Chair: Erle Lim (Singapore)
14:30 – 15:00	EMG Marina de Koning-Tijssen (Groningen, Netherlands)
15:00 – 15:30	Ultrasound Katharine Alter (Bethesda, MD, USA)
15:30 – 16:00	Other Techniques, Including Inspection, Palpation, Anatomic Landmarks Erle Lim (Singapore)
16:00 – 16:30	Break
16:30 – 18:00	Treatment of Tremor With BoNT Chair: Dirk Dressler (Hannover, Germany)
16:30 – 17:00	Approach to Hand Tremors Seth Pullman (New York, NY, USA)
17:00 – 17:30	Head Tremor Wolfgang Jost (Wiesbaden, Germany)
17:30 – 18:00	Voice Tremor Robert Bastian (Downers Grove, IL, USA)

Parallel Track I (Clinical)
14:30 – 16:00	Clinical Pearls: Optimizing Outcomes in Blepharospasm and Hemifacial Spasm Chair: Giovanni DeFazio (Bari, Italy)
14:30 – 15:00	Diagnosis of Blepharospasm: Are We There Yet? Giovanni DeFazio (Bari, Italy)
15:00 – 15:30	Is There One Toxin/Dose That is Superior to Another for Blepharospasm/Hemifacial Spasm (HFS)? Anna Rita Bentivoglio (Rome, Italy)
15:30 – 16:00	How to Inject for Optimal Outcome Earl Consky (Toronto, Canada)
16:00 – 16:30	Break
16:30 – 17:00	Platform Session − Long-Term Studies of BoNT Efficacy, Safety, and Responsiveness Chairs: Giovanni DeFazio (Bari, Italy) and Peter Moore (Liverpool, UK)
16:30 – 16:40	Treatment Patterns and Patient Disposition in the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE) Cynthia Comella (Chicago, IL, USA)
16:40 – 16:50	Efficacy of IncobotulinumtoxinA in Poststroke Upper Limb Spasticity: Results From a Large Multicenter 1-Year Noninterventional Study Dirk Dressler (Hannover, Germany)
16:50 – 17:00	Botulinum Toxin in Sialorrhea Is Safe and Effective in Long-Term Use Martina Petracca (Rome, Italy)
17:00 – 18:30	Considerations When Botulinum Toxin Treatment Is Not Effective Chair: Peter Moore (Liverpool, UK)
17:00 – 17:30	The Many Causes of Secondary Nonresponse Cynthia Comella (Chicago, IL, USA)
17:30 – 18:00	Molecular Basis of Immunogenicity to Botulinum Neurotoxins M. Zouhair Atassi (Houston, TX, USA)
18:00 – 18:30	Assessing Antibodies to Botulinum Toxin Dirk Dressler (Hannover, Germany)

176. The ComCal to facilitate the communication between physicians and physiotherapists in botulinum neurotoxin therapy of spasticity

Toxicon, Volume 93, Supplement, January 2015, Page S55
Fereshte Adib Saberi, Heidrun M. Pickenbrock, Dirk Dressler

67. Economics of botulinum toxin therapy: influence of the abobotulinumtoxinA package size on the costs of botulinum neurotoxin therapy

Toxicon, Volume 93, Supplement, January 2015, Pages S21-S22
Dirk Dressler, Fereshte Adib Saberi

63. Botulinum neurotoxin therapy: reduction of injection site pain by pH normalization

Toxicon, Volume 93, Supplement, January 2015, Pages S20-S21
Dirk Dressler, Fereshte Adib Saberi, Hans Bigalke

68. Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin)

Toxicon, Volume 93, Supplement, January 2015, Page S22
Dirk Dressler, Pawel Tacik, Fereshte Adib Saberi

64. Botulinum neurotoxin therapy of cervical dystonia: duration of therapeutic effects

Toxicon, Volume 93, Supplement, January 2015, Page S21
Dirk Dressler, Pawel Tacik, Fereshte Adib Saberi

65. Efficacy of incobotulinumtoxinA in poststroke upper limb spasticity: results from a large multicenter 1-year noninterventional study

Toxicon, Volume 93, Supplement, January 2015, Page S21
Dirk Dressler, Reinhard Rychlik, Nicole Schnur, Judith Lambert-Baumann

66. Mouse diaphragm assay confirms identical potency labeling for onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin)

Toxicon, Volume 93, Supplement, January 2015, Page S21
Dirk Dressler, Hans Bigalke

83. Use of concomitant therapies in real-life clinical management of patients with poststroke upper limb spasticity treated with botulinum toxin: German-Austrian subgroup of the ULIS II study

Toxicon, Volume 93, Supplement, January 2015, Page S26
Klemens Fheodoroff, Dirk Dressler, Hartwig Woldag, Peter Kossmehl, Gerhard Reichel

151. Botulinum neurotoxin therapy for hyperhidrosis: reduction of injection site pain by nitrous oxide/oxygen mixtures

Toxicon, Volume 93, Supplement, January 2015, Page S47
Lejla Paracka, Katja Kollewe, Dirk Dressler

100. Children are not little adults—dosage and development do matter

Toxicon, Volume 93, Supplement, January 2015, Pages S30-S31
Florian Heinen, Steffen Berweck, A. Sebastian Schroeder

24. Managing drooling in cerebral palsy

Toxicon, Volume 93, Supplement, January 2015, Page S9
Steffen Berweck, A. Sebastian Schroeder, Christine Jansen, Florian Heinen